Weiner Michael W, Veitch Dallas P, Aisen Paul S, Beckett Laurel A, Cairns Nigel J, Cedarbaum Jesse, Donohue Michael C, Green Robert C, Harvey Danielle, Jack Clifford R, Jagust William, Morris John C, Petersen Ronald C, Saykin Andrew J, Shaw Leslie, Thompson Paul M, Toga Arthur W, Trojanowski John Q
Department of Veterans Affairs Medical Center, Center for Imaging of Neurodegenerative Diseases, San Francisco, CA, USA; Department of Radiology, University of California, San Francisco, San Francisco, CA, USA; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA; Department of Psychiatry, University of California, San Francisco, San Francisco, CA, USA; Department of Neurology, University of California, San Francisco, San Francisco, CA, USA.
Department of Veterans Affairs Medical Center, Center for Imaging of Neurodegenerative Diseases, San Francisco, CA, USA.
Alzheimers Dement. 2015 Jul;11(7):865-84. doi: 10.1016/j.jalz.2015.04.005.
The Alzheimer's Disease Neuroimaging Initiative (ADNI) was established in 2004 to facilitate the development of effective treatments for Alzheimer's disease (AD) by validating biomarkers for AD clinical trials.
We searched for ADNI publications using established methods.
ADNI has (1) developed standardized biomarkers for use in clinical trial subject selection and as surrogate outcome measures; (2) standardized protocols for use across multiple centers; (3) initiated worldwide ADNI; (4) inspired initiatives investigating traumatic brain injury and post-traumatic stress disorder in military populations, and depression, respectively, as an AD risk factor; (5) acted as a data-sharing model; (6) generated data used in over 600 publications, leading to the identification of novel AD risk alleles, and an understanding of the relationship between biomarkers and AD progression; and (7) inspired other public-private partnerships developing biomarkers for Parkinson's disease and multiple sclerosis.
ADNI has made myriad impacts in its first decade. A competitive renewal of the project in 2015 would see the use of newly developed tau imaging ligands, and the continued development of recruitment strategies and outcome measures for clinical trials.
阿尔茨海默病神经影像学计划（ADNI）于2004年设立，旨在通过验证用于阿尔茨海默病（AD）临床试验的生物标志物，推动AD有效治疗方法的开发。
我们采用既定方法检索ADNI相关出版物。
ADNI已（1）开发出标准化生物标志物，用于临床试验受试者选择及作为替代结局指标；（2）制定了多中心通用的标准化方案；（3）启动了全球范围的ADNI；（4）激发了分别针对军事人群中创伤性脑损伤和创伤后应激障碍以及抑郁症作为AD风险因素的研究计划；（5）充当了数据共享模型；（6）生成的数据被用于600多篇出版物中，促成了新型AD风险等位基因的识别以及对生物标志物与AD进展之间关系的理解；（7）激发了其他公私合作项目开发帕金森病和多发性硬化症的生物标志物。
ADNI在其首个十年产生了诸多影响。2015年该项目的竞争性续约将涉及新开发的tau成像配体的使用，以及临床试验招募策略和结局指标的持续开发。
